To me, patient centricity is as fascinating a concept as it is contradictory. It is fascinating because it puts power into the hands of the patient. And it is contradictory because pharma does not like giving away power over its messages or processes. Pharma has traditionally never enjoyed interaction and has depended on ‘pushing’ messages across rather than having ‘conversations’. It probably also explains why we make do with medical reps who are not the sharpest knives in the drawer and scarcely invest in sharpening them.

Can Medicines Inject the Vitamins Amazon is Missing?

How Amazon’s Healthcare Bet May Change Indian Diagnostics and...

Culture and Resistance to Change – A Pharma SFE Adoption Case Study

As an MNC Head, I was one among the...

IMS Health Market Reflection Report for June 2016

Every month, MedicinMan in partnership with IMS Health, brings our readers the latest industry numbers related to sales and revenues of different companies, brands and therapy areas in the Indian Pharmaceutical Market.

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars

India's pharmaceutical market charged into 2026 with strong momentum,...

How Smart Medical Reps Can Beat Bots

Today's Brand Equity cover — a woman lost in...

Nutraceuticals: Health, Hope Or Hype?

Walk into almost any clinic today and you will...

When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies

“Lifestyle advice often asks patients to fight powerful evolutionary...

The Antifungal Blind Spot: India’s Quiet Clinical Crisis

A market analysis and clinical commentary on the growing...

Marketing

IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars

India's pharmaceutical market charged into 2026 with strong momentum,...

How Smart Medical Reps Can Beat Bots

Today's Brand Equity cover — a woman lost in...

Nutraceuticals: Health, Hope Or Hype?

Walk into almost any clinic today and you will...

When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies

“Lifestyle advice often asks patients to fight powerful evolutionary...

The Antifungal Blind Spot: India’s Quiet Clinical Crisis

A market analysis and clinical commentary on the growing...

Policies/Sales

IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars

India's pharmaceutical market charged into 2026 with strong momentum,...

How Smart Medical Reps Can Beat Bots

Today's Brand Equity cover — a woman lost in...

Nutraceuticals: Health, Hope Or Hype?

Walk into almost any clinic today and you will...

When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies

“Lifestyle advice often asks patients to fight powerful evolutionary...

The Antifungal Blind Spot: India’s Quiet Clinical Crisis

A market analysis and clinical commentary on the growing...

Strategy

IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars

India's pharmaceutical market charged into 2026 with strong momentum,...

How Smart Medical Reps Can Beat Bots

Today's Brand Equity cover — a woman lost in...

Nutraceuticals: Health, Hope Or Hype?

Walk into almost any clinic today and you will...

When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies

“Lifestyle advice often asks patients to fight powerful evolutionary...

The Antifungal Blind Spot: India’s Quiet Clinical Crisis

A market analysis and clinical commentary on the growing...

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

The ‘Amazonization’ of Healthcare

Inside this Issue 1. The 'Amazonization' of Healthcare by Salil Kallianpur Amazon's drive...

Dr. Tarun Gupta Tribute Issue

Editor's Note - This issue of MedicinMan is dedicated to the memory of Dr. Tarun Gupta, TG as he was fondly called. Executive Editor, Salil Kallianpur, dear friend Subrato Banerjee and long-time MedicinMan patron Vivek Hattangadi, pen their tributes to TG.

Pharma and the Covid19 Crisis – An Interaction with Sunil Attavar, CMD, Group Pharma

This is the first part of MedicinMan interview series...

Cipla–Pfizer Deal: How “Ordinary” Brands Are Fueling an Extraordinary Power Shift in Indian Pharma

What’s really happening in the Cipla–Pfizer tie‑up At first glance,...

Medical Rep to Chairman & Managing Director – Sunil Attavar’s Success Story

Q 1. Tell us about your journey as a pharma entrepreneur and what made you venture into pharma and stay on in pharma? My journey started with two good decisions, one- to be a Medical Representative (MR) in Mumbai, which built a strong foundation and the other, to join Helios, a new pharma company, which was like a baptism of fire. Together, they molded me well. I was promoted as a Front Line Manager (FLM) within a year. And after spending four excellent years in Helios, I joined Group Pharma as Product Manager (PM) and ever since, it’s been an exciting learning experience. I was exposed to Pharma very early in life as my dad was in J L Morison, as part of the promoter-team of Warren Pharma. At home, I was the designated telephone operator and order processing clerk. Those were the days of trunk-calls - calling managers and distributors to note down orders. Hence, I was exposed to the excitement of targets, achievements, deficits and campaigns very early in my life. The idea of ‘work-life balance’ was not in vogue. One would look to their parents who worked long hours with pride making it something you wanted to emulate. Things have changed a lot but I would not trade the decision I made, to get into and stay in Pharma.